Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2016 | 09-2016 | 06-2016 | 03-2016 | 12-2015 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -17,681 | -9,166 | -4,824 | -13,102 | -38,956 |
| Depreciation Amortization | 3 | 95 | 65 | 6 | 107 |
| Income taxes - deferred | -41 | N/A | N/A | N/A | 365 |
| Accounts payable and accrued liabilities | N/A | -703 | -324 | -578 | -289 |
| Other Working Capital | 1,353 | -1,795 | -772 | -1,410 | -4,127 |
| Other Operating Activity | 4,516 | -25,346 | -18,852 | 1,868 | -5,260 |
| Operating Cash Flow | $-11,850 | $-36,915 | $-24,707 | $-13,216 | $-48,160 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | -6 | -6 | -6 | -153 |
| Other Investing Activity | -85 | -1,050 | -1,050 | -1,050 | 10,548 |
| Investing Cash Flow | $-85 | $-1,056 | $-1,056 | $-1,056 | $10,395 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 16,500 | 23,641 | 23,641 | -1,030 | N/A |
| Debt Repayment | N/A | -23,279 | -28,779 | N/A | -3,911 |
| Common Stock Issued | N/A | 32,393 | 20,528 | 20,281 | 47,756 |
| Common Stock Repurchased | N/A | N/A | 233 | N/A | N/A |
| Financing Cash Flow | $16,500 | $32,755 | $15,623 | $19,251 | $43,845 |
| Beginning Cash Position | 1,397 | 29,730 | 29,730 | 29,730 | 23,650 |
| End Cash Position | 5,962 | 24,514 | 19,590 | 34,709 | 29,730 |
| Net Cash Flow | $4,565 | $-5,216 | $-10,140 | $4,979 | $6,080 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,850 | -36,915 | -24,707 | -13,216 | -48,160 |
| Capital Expenditure | N/A | -6 | -6 | -6 | -153 |
| Free Cash Flow | -11,850 | -36,921 | -24,713 | -13,222 | -48,313 |